Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Manage my Boston Scientific account

Quick Links

Contact a representative
Online education and training
Order products online
Reimbursement resources
Return a product
Customer support

Call customer care

1 (888) 272-1001

women seating in front of microscope with all protecting gear

Interventional Cardiology Therapies

Our focus

Minimally invasive technologies to improve the lives of patients living with heart and vascular conditions.

Rod’s story

We’re committed to advancing interventional cardiology therapies through less invasive technologies that improve outcomes, deliver care to more patients, reduce costs, and help millions live healthier lives.

Delivering meaningful innovation

Modern approach to percutaneous coronary intervention (PCI).

A comprehensive portfolio of PCI devices and training designed to help interventional cardiologists provide patients with complex coronary artery disease the best possible treatment and quality of life.

Peace of mind.

The SENTINEL™ Cerebral Protection System (CPS) is the first and only commercially available device in the U.S. offering protected transcatheter aortic valve replacement (TAVR) – proven embolic protection against the risk of TAVR-related stroke.

Healing with confidence.

 Available in a portfolio with distinct options to treat the unique needs of patients, the SYNERGY™ Bioabsorbable Polymer Stent is intentionally designed with thin struts and a fast-absorbing bioabsorbable polymer coating, which enable rapid healing and shortened dual-antiplatelet therapy.  

~200

lives impacted every hour by Boston Scientific Interventional Cardiology Therapies.1

> 100k patients

treated worldwide with the AGENTTM Drug-Coated Balloon.1

>18.4 million

coronary drug eluting stent implants globally.1

>5.6 million

SYNERGY™ Bioabsorbable Polymer Stent implants.1

Conditions we treat

  • Cardiovascular Diseases
  • Coronary Artery Disease

~6M

patients undergo PCIs worldwide annually.2

< 1/3

up to one-third of all percutaneous coronary interventions may be complicated by moderate-to-severe calcium.9

~7%

of all people over the age of 65 affected by aortic stenosis.3

~3.5M

patients with moderate-severe mitral regurgitation.4

Solutions we offer

  • Cerebral Embolic Protection (CEP)
  • Drug-Eluting Technologies
  • Complex Percutaneous Coronary Intervention (PCI)
  • PCI Guidance
  • Calcium Treatment

Product spotlights

SENTINEL Cerebral Protection System

AGENT™ Drug-Coated Balloon

The AGENT™ Drug-Coated Balloon is the first and only coronary drug-coated balloon approved for use in the U.S. Available in global markets since 2014, AGENT expands treatment options for patients with coronary artery disease who experience in-stent restenosis by delivering a targeted anti-stenotic drug dose without an extra layer of metal.

Learn more about the AGENT Drug-Coated Balloon
SENTINEL Cerebral Protection System

SENTINEL™ Cerebral Protection System (CPS)

The SENTINEL Cerebral Protection System offers protection from the risk of stroke during TAVR. It works by capturing embolic debris dislodged during TAVR before it can reach the brain. Clinical trials involving more than 5,000 patients patients have demonstrated that the SENTINEL device is safe and effective. This technology has been used to protect thousands of patients worldwide and is the most-studied embolic protection device in its field.5-7

Learn more about the SENTINEL CPS
SYNERGY BP Stent

SYNERGY™ XD Bioabsorbable Polymer Stent System

The SYNERGY XD BP Stent is a next-generation drug-eluting stent with a bioabsorbable polymer coating designed to address the challenges associated with permanent polymer stents such as inflammation, neoatherosclerosis, and late stent thrombosis. The enhanced delivery system enables better navigation of challenging anatomies.

The SYNERGY XD BP Stent provides synchronous drug elution and polymer absorption providing rapid healing and freedom from long-term polymer exposure. In more than 17,000 patients across 14 studies, this technology demonstrated outstanding safety with consistently low stent thrombosis rates.8

Learn more about the SYNERGY XD
AVVIGO Guidance System II

AVVIGO™+ Multi-Modality Guidance System 

The AVVIGO™+ Multi-Modality Guidance System is a streamlined software and hardware platform that provides high-quality intravascular imaging (IVUS) and physiology experience. The new platform is designed with several features to enable faster, more efficient procedures for patients with coronary artery disease, including a machine learning algorithm to provide physicians with automated and precise vessel measurements.

Learn more about the AVVIGO+ Multi-Modality Guidance System

Sources

  1. Internal Boston Scientific data
  2. Internal Boston Scientific estimate
  3. Arora, et al. Transcatheter Aortic Valve Replacement: Comprehensive Review and Present Status. Tex Heart Inst J. 2017 Feb 1;44(1):29-38. doi: 10.14503/THIJ16-5852. 
  4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974123/
  5. Van Mieghem N. Snapshots from Real World High Volume Single Center Experiences with Sentinel Cerebral Embolic Protection During TAVR, Erasmus Medical Center, presented at TVT 2018. 
  6. Seeger J. Snapshots from Real World High Volume Single Center Experiences with Sentinel Cerebral Embolic Protection During TAVR, University of Ulm, presented at TVT 2018. 
  7. Chakravarty T. Snapshots from Real World High Volume Single Center Experiences with Sentinel Cerebral Embolic Protection During TAVR, Cedars Sinai Medical Center, presented at TVT 2018.
  8. EVOLVE: Meredith IT, et al. EuroInterv. 2018;13:2047-2050., EVOLVE II: Kereiakes D, et al. Circ Cardiovasc Interv. 2015;8:e002372. DOI:10.1161/CIRCINTERVENTIONS.114.002372., SCAAR Registry: Sarno G, et al. Catheter Cardiovasc Interv. 2017;90:881-887., BIO-RESORT: Birgelen CV, et al. Lancet. 2016; 388:2607-17., SENIOR: Varenne O, et al. Lancet. 2018;391(10115):45-50., SORT OUT VIII: Maeng M, et al. JACC: Cardiovasc Interv. 2019; 7(12):624-33., SYNERGY ACS Registry: Presented by Jose M de la Torre Hernandez, MD at EuroPCR 2018., EVOLVE Short DAPT: Kirtane AJ, et al. Circ Cardiovasc Interv. 2021;14:e010144. doi:10.1161/CIRCINTERVENTIONS.120.010144., EVOLVE 48: Karmpaliotis D, et al. Catheter Cardiovasc Interv. doi:10.1002/ccd.29798., POEM: Pivato CA, et al. J Am Heart Assoc. 2022;11:e023454. DOI: 10.1161/JAHA.121.023454., ASET: Kogame N, et al. J Am Coll Cardiol Intv. 2020;13:2251–62. CLEAR SYNERGY: Jolly S, et al. J Am Coll Cardiol. 2024;220:111-117., ASEAN SYNERGY: Presented by Hui Wen Sim, MD at EuroPCR 2024., OPTIVUS-Complex PCI: Yamamoto K, et al. JACC: Asia. 2023;3(2):211-225; Presented by Ryusuke Nishikawa, MD at ACC 2025. 14 Studies – SYNERGY patients: EVOLVE: 193, EVOLVE II: 831, SCAAR: 4,247, BIO-RESORT: 1,172, SENIOR: 1,200, SORT OUT VIII: 1385, SYNERGY ACS Registry: 1,008, EVOLVE Short DAPT: 1487, EVOLVE 48: 100, POEM: 443, ASET: 201, CLEAR SYNERGY: 733, ASEAN SYNERGY: 2,104, OPTIVUS-Complex PCI: 1,017+902=1,919
  9. Source: Généreux, P. et al. J Am Coll Cardiol 2014 May;63(18):1845-1854.